Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A randomized, single-blinded, multicenter, Phase IV study to compare systemic VEGF protein dynamics following monthly intravitreal injections of 0.5 mg ranibizumab versus 2 mg aflibercept until Week 12 in patients with neovascular (wet) age-related macular degeneration (TIDE AMD)

    Summary
    EudraCT number
    2014-001182-27
    Trial protocol
    DE  
    Global end of trial date
    08 Jun 2017

    Results information
    Results version number
    v1(current)
    This version publication date
    20 Jun 2018
    First version publication date
    20 Jun 2018
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    CRFB002ADE27
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT02257632
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    Novartis Pharma AG
    Sponsor organisation address
    CH-4002, Basel, Switzerland,
    Public contact
    Clinical Disclosure Office, Novartis Pharma AG, 41 613241111, Novartis.email@novartis.com
    Scientific contact
    Clinical Disclosure Office, Novartis Pharma AG, 41 613241111, Novartis.email@novartis.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    08 Jun 2017
    Is this the analysis of the primary completion data?
    No
    Global end of trial reached?
    Yes
    Global end of trial date
    08 Jun 2017
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    The primary objective of this study was to compare systemic VEGF-A protein levels following monthly intravitreal injections of 0.5 mg ranibizumab for 3 months vs. monthly intravitreal injections of 2 mg aflibercept for 3 months, as measured by the area under the curve (AUC) from Baseline to Week 12.
    Protection of trial subjects
    The study was in compliance with the ethical principles derived from the Declaration of Helsinki and the International Conference on Harmonization (ICH) Good Clinical Practice (GCP) guidelines. All the local regulatory requirements pertinent to safety of trial subjects were also followed during the conduct of the trial.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    08 Apr 2015
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Germany: 40
    Worldwide total number of subjects
    40
    EEA total number of subjects
    40
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    3
    From 65 to 84 years
    32
    85 years and over
    5

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    The study included adult patients with active, newly diagnosed, and untreated wAMD. In total, 41 patients were randomized. One patient was randomized unintendedly and not treated. This patient was not included in any analyses. A total of 40 patients were treated at 6 study sites across Germany. Patients were treated in an outpatient setting.

    Pre-assignment
    Screening details
    At Screening, the eligibility criteria were performed.

    Period 1
    Period 1 title
    Overall Study (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Randomised - controlled
    Blinding used
    Single blind [1]
    Roles blinded
    Subject, Data analyst, Assessor

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Group 1
    Arm description
    6 monthly intravitreal injections of 0.5 mg ranibizumab
    Arm type
    Experimental

    Investigational medicinal product name
    Ranibizumab
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for injection
    Routes of administration
    Intraocular use
    Dosage and administration details
    6 monthly intravitreal injections of 0.5 mg ranibizumab

    Arm title
    Group 2
    Arm description
    3 monthly intravitreal injections of 2 mg aflibercept followed by 3 monthly intravitreal injections of 0.5 mg ranibizumab
    Arm type
    Active comparator

    Investigational medicinal product name
    Aflibercept
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for injection
    Routes of administration
    Intraocular use
    Dosage and administration details
    3 monthly intravitreal injections of 2 mg aflibercept followed by 3 monthly intravitreal injections of 0.5 mg ranibizumab

    Notes
    [1] - The number of roles blinded appears inconsistent with a single blinded trial. It is expected that there will be one role blinded in a single blind trial.
    Justification: The study was performed in a single-blinded fashion. Only patients, staff performing BCVA assessments, CRC staff, laboratory staff, and data analysts remained blinded to the identity of the treatment from the time of randomization until database lock.
    Number of subjects in period 1
    Group 1 Group 2
    Started
    19
    21
    Full Analysis Set (FAS)
    19
    21
    Safety Set (SAF)
    19
    21
    Completed
    18
    19
    Not completed
    1
    2
         Adverse event, non-fatal
    1
    2

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Group 1
    Reporting group description
    6 monthly intravitreal injections of 0.5 mg ranibizumab

    Reporting group title
    Group 2
    Reporting group description
    3 monthly intravitreal injections of 2 mg aflibercept followed by 3 monthly intravitreal injections of 0.5 mg ranibizumab

    Reporting group values
    Group 1 Group 2 Total
    Number of subjects
    19 21 40
    Age categorical
    Units: Subjects
        In utero
    0 0 0
        Preterm newborn infants (gestational age < 37 wks)
    0 0 0
        Newborns (0-27 days)
    0 0 0
        Infants and toddlers (28 days-23 months)
    0 0 0
        Children (2-11 years)
    0 0 0
        Adolescents (12-17 years)
    0 0 0
        Adults (18-64 years)
    0 3 3
        From 65-84 years
    18 14 32
        85 years and over
    1 4 5
    Age Continuous
    Units: Years
        arithmetic mean (standard deviation)
    74.3 ( 5.50 ) 75.4 ( 8.94 ) -
    Sex/Gender, Customized
    Units: Subjects
        Female|
    11 10 21
        Male|
    8 11 19
    Race/Ethnicity, Customized
    Units: Subjects

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Group 1
    Reporting group description
    6 monthly intravitreal injections of 0.5 mg ranibizumab

    Reporting group title
    Group 2
    Reporting group description
    3 monthly intravitreal injections of 2 mg aflibercept followed by 3 monthly intravitreal injections of 0.5 mg ranibizumab

    Primary: Standardized Area Under the Curve (AUC) for VEGF A levels by SIMOA (Quanterix’s single molecule array) method for the comparative phase

    Close Top of page
    End point title
    Standardized Area Under the Curve (AUC) for VEGF A levels by SIMOA (Quanterix’s single molecule array) method for the comparative phase
    End point description
    The AUC was calculated using the trapezoidal rule, where all available measurement between Day 1 and Week 12 were used. The AUC was standardized by dividing the calculated value by the number of days from first to last measurement.
    End point type
    Primary
    End point timeframe
    Baseline up to Week 12 visit (Days 1, 2, 8, 15, 29, 43, 57, 71, 85)
    End point values
    Group 1 Group 2
    Number of subjects analysed
    17
    20
    Units: pg/mL
        arithmetic mean (standard deviation)
    18.78 ( 8.460 )
    33.95 ( 7.659 )
    Statistical analysis title
    AUC for VEGF A levels for the comparative phase
    Comparison groups
    Group 1 v Group 2
    Number of subjects included in analysis
    37
    Analysis specification
    Pre-specified
    Analysis type
    P-value
    < 0.0001 [1]
    Method
    ANCOVA
    Parameter type
    Mean difference (final values)
    Point estimate
    -14.98
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -19.64
         upper limit
    -10.32
    Notes
    [1] - missing Baseline VEGF-A level covariate values were imputed by the mean value of non-missing Baseline VEGF-A level from all other patients

    Secondary: Systemic VEGF-A protein levels from study week 12 to 24

    Close Top of page
    End point title
    Systemic VEGF-A protein levels from study week 12 to 24
    End point description
    Systemic VEGF-A protein levels in patients switching from monthly 2 mg aflibercept injections to monthly 0.5 mg ranibizumab compared to patients treated with monthly 0.5 mg ranibizumab from baseline (standardized area under the curve)
    End point type
    Secondary
    End point timeframe
    From study week 12 to 24 (Days 85, 99, 113, 127, 141, 155, 169)
    End point values
    Group 1 Group 2
    Number of subjects analysed
    17
    20
    Units: pg/mL
        arithmetic mean (standard deviation)
    17.93 ( 5.316 )
    29.07 ( 7.863 )
    Statistical analysis title
    VEGF-A protein levels from study week 12 to 24
    Comparison groups
    Group 1 v Group 2
    Number of subjects included in analysis
    37
    Analysis specification
    Pre-specified
    Analysis type
    P-value
    < 0.0001 [2]
    Method
    ANCOVA
    Parameter type
    Mean difference (final values)
    Point estimate
    -11.46
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -15.98
         upper limit
    -6.94
    Notes
    [2] - missing Baseline VEGF-A level covariate values were imputed by the mean value of non-missing Baseline VEGF-A level from all the patients with values

    Secondary: Systemic VEGF-A levels from study week 12 to 24 (change from baseline)

    Close Top of page
    End point title
    Systemic VEGF-A levels from study week 12 to 24 (change from baseline)
    End point description
    Adjustment of systemic VEGF-A levels of patients switching from aflibercept to ranibizumab to levels comparable to baseline or to levels comparable as in patients treated from baseline with ranibizumab
    End point type
    Secondary
    End point timeframe
    From study week 12 to 24
    End point values
    Group 1 Group 2
    Number of subjects analysed
    17
    20
    Units: pg/ml
    arithmetic mean (standard deviation)
        Change from Baseline at Week 12|
    -1.37 ( 5.369 )
    23.73 ( 13.700 )
        Change from Baseline at Week 14|
    -1.00 ( 6.128 )
    21.93 ( 15.638 )
        Change from Baseline at Week 16|
    -0.01 ( 4.675 )
    19.26 ( 16.432 )
        Change from Baseline at Week 18|
    1.99 ( 5.582 )
    11.61 ( 10.844 )
        Change from Baseline at Week 20|
    1.62 ( 6.460 )
    4.84 ( 11.065 )
        Change from Baseline at Week 22|
    0.66 ( 8.109 )
    2.45 ( 8.543 )
        Change from Baseline at Week 24|
    -1.18 ( 3.664 )
    0.96 ( 9.553 )
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    Adverse Events are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV).  All Adverse events are reported in this record from First Patient First Treatment until Last Patient Last Visit.
    Adverse event reporting additional description
    Adverse events that occurred in Group 2 are reported in Group 2 irrespective of treatment (Aflibercept, followed by ranibizumab)
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    20.0
    Reporting groups
    Reporting group title
    Aflibercept 2 mg
    Reporting group description
    Aflibercept 2 mg

    Reporting group title
    Ranibizumab 0.5 mg
    Reporting group description
    Ranibizumab 0.5 mg

    Serious adverse events
    Aflibercept 2 mg Ranibizumab 0.5 mg
    Total subjects affected by serious adverse events
         subjects affected / exposed
    3 / 19 (15.79%)
    3 / 21 (14.29%)
         number of deaths (all causes)
    0
    0
         number of deaths resulting from adverse events
    0
    0
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Benign lung neoplasm
         subjects affected / exposed
    1 / 19 (5.26%)
    0 / 21 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cardiac disorders
    Atrial fibrillation
         subjects affected / exposed
    0 / 19 (0.00%)
    1 / 21 (4.76%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 4
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cardiac failure congestive
         subjects affected / exposed
    0 / 19 (0.00%)
    1 / 21 (4.76%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Eye disorders
    Optic nerve cupping
         subjects affected / exposed
    0 / 19 (0.00%)
    1 / 21 (4.76%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Retinal pigment epithelial tear
         subjects affected / exposed
    1 / 19 (5.26%)
    0 / 21 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Musculoskeletal and connective tissue disorders
    Bone cyst
         subjects affected / exposed
    1 / 19 (5.26%)
    0 / 21 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Infections and infestations
    Pneumonia
         subjects affected / exposed
    1 / 19 (5.26%)
    0 / 21 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 3%
    Non-serious adverse events
    Aflibercept 2 mg Ranibizumab 0.5 mg
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    16 / 19 (84.21%)
    20 / 21 (95.24%)
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Basal cell carcinoma
         subjects affected / exposed
    2 / 19 (10.53%)
    0 / 21 (0.00%)
         occurrences all number
    2
    0
    Vascular disorders
    Hypertension
         subjects affected / exposed
    0 / 19 (0.00%)
    1 / 21 (4.76%)
         occurrences all number
    0
    2
    Intermittent claudication
         subjects affected / exposed
    1 / 19 (5.26%)
    0 / 21 (0.00%)
         occurrences all number
    1
    0
    Surgical and medical procedures
    Jaw operation
         subjects affected / exposed
    1 / 19 (5.26%)
    0 / 21 (0.00%)
         occurrences all number
    1
    0
    General disorders and administration site conditions
    Fibrosis
         subjects affected / exposed
    0 / 19 (0.00%)
    1 / 21 (4.76%)
         occurrences all number
    0
    1
    Influenza like illness
         subjects affected / exposed
    0 / 19 (0.00%)
    1 / 21 (4.76%)
         occurrences all number
    0
    1
    Injection site pain
         subjects affected / exposed
    1 / 19 (5.26%)
    1 / 21 (4.76%)
         occurrences all number
    1
    1
    Sensation of foreign body
         subjects affected / exposed
    0 / 19 (0.00%)
    2 / 21 (9.52%)
         occurrences all number
    0
    2
    Immune system disorders
    Hypersensitivity
         subjects affected / exposed
    0 / 19 (0.00%)
    1 / 21 (4.76%)
         occurrences all number
    0
    2
    Respiratory, thoracic and mediastinal disorders
    Bronchial wall thickening
         subjects affected / exposed
    1 / 19 (5.26%)
    0 / 21 (0.00%)
         occurrences all number
    1
    0
    Nasal congestion
         subjects affected / exposed
    0 / 19 (0.00%)
    1 / 21 (4.76%)
         occurrences all number
    0
    1
    Oropharyngeal pain
         subjects affected / exposed
    0 / 19 (0.00%)
    2 / 21 (9.52%)
         occurrences all number
    0
    2
    Pleural effusion
         subjects affected / exposed
    1 / 19 (5.26%)
    0 / 21 (0.00%)
         occurrences all number
    1
    0
    Pulmonary embolism
         subjects affected / exposed
    1 / 19 (5.26%)
    0 / 21 (0.00%)
         occurrences all number
    1
    0
    Psychiatric disorders
    Anxiety
         subjects affected / exposed
    0 / 19 (0.00%)
    1 / 21 (4.76%)
         occurrences all number
    0
    1
    Insomnia
         subjects affected / exposed
    1 / 19 (5.26%)
    1 / 21 (4.76%)
         occurrences all number
    1
    1
    Investigations
    Blood pressure increased
         subjects affected / exposed
    1 / 19 (5.26%)
    0 / 21 (0.00%)
         occurrences all number
    1
    0
    Body temperature increased
         subjects affected / exposed
    1 / 19 (5.26%)
    1 / 21 (4.76%)
         occurrences all number
    1
    1
    Electrocardiogram abnormal
         subjects affected / exposed
    1 / 19 (5.26%)
    0 / 21 (0.00%)
         occurrences all number
    1
    0
    Gamma-glutamyltransferase increased
         subjects affected / exposed
    1 / 19 (5.26%)
    0 / 21 (0.00%)
         occurrences all number
    1
    0
    Haemoglobin E present
         subjects affected / exposed
    1 / 19 (5.26%)
    0 / 21 (0.00%)
         occurrences all number
    1
    0
    Intraocular pressure increased
         subjects affected / exposed
    1 / 19 (5.26%)
    2 / 21 (9.52%)
         occurrences all number
    1
    4
    Mean cell haemoglobin concentration increased
         subjects affected / exposed
    1 / 19 (5.26%)
    0 / 21 (0.00%)
         occurrences all number
    1
    0
    Mean cell haemoglobin increased
         subjects affected / exposed
    1 / 19 (5.26%)
    0 / 21 (0.00%)
         occurrences all number
    1
    0
    Injury, poisoning and procedural complications
    Fall
         subjects affected / exposed
    1 / 19 (5.26%)
    1 / 21 (4.76%)
         occurrences all number
    1
    1
    Hand fracture
         subjects affected / exposed
    1 / 19 (5.26%)
    0 / 21 (0.00%)
         occurrences all number
    1
    0
    Laceration
         subjects affected / exposed
    0 / 19 (0.00%)
    1 / 21 (4.76%)
         occurrences all number
    0
    1
    Cardiac disorders
    Aortic valve disease
         subjects affected / exposed
    1 / 19 (5.26%)
    0 / 21 (0.00%)
         occurrences all number
    1
    0
    Aortic valve incompetence
         subjects affected / exposed
    0 / 19 (0.00%)
    1 / 21 (4.76%)
         occurrences all number
    0
    1
    Atrial fibrillation
         subjects affected / exposed
    0 / 19 (0.00%)
    1 / 21 (4.76%)
         occurrences all number
    0
    1
    Cardiac discomfort
         subjects affected / exposed
    1 / 19 (5.26%)
    0 / 21 (0.00%)
         occurrences all number
    1
    0
    Cardiac fibrillation
         subjects affected / exposed
    0 / 19 (0.00%)
    1 / 21 (4.76%)
         occurrences all number
    0
    1
    Cardiovascular disorder
         subjects affected / exposed
    1 / 19 (5.26%)
    0 / 21 (0.00%)
         occurrences all number
    1
    0
    Mitral valve incompetence
         subjects affected / exposed
    0 / 19 (0.00%)
    1 / 21 (4.76%)
         occurrences all number
    0
    1
    Sinus bradycardia
         subjects affected / exposed
    1 / 19 (5.26%)
    0 / 21 (0.00%)
         occurrences all number
    1
    0
    Tricuspid valve incompetence
         subjects affected / exposed
    0 / 19 (0.00%)
    1 / 21 (4.76%)
         occurrences all number
    0
    1
    Nervous system disorders
    Burning sensation
         subjects affected / exposed
    0 / 19 (0.00%)
    1 / 21 (4.76%)
         occurrences all number
    0
    1
    Headache
         subjects affected / exposed
    2 / 19 (10.53%)
    1 / 21 (4.76%)
         occurrences all number
    3
    1
    Monoparesis
         subjects affected / exposed
    1 / 19 (5.26%)
    0 / 21 (0.00%)
         occurrences all number
    1
    0
    Sciatica
         subjects affected / exposed
    1 / 19 (5.26%)
    0 / 21 (0.00%)
         occurrences all number
    1
    0
    Ear and labyrinth disorders
    Vertigo
         subjects affected / exposed
    1 / 19 (5.26%)
    0 / 21 (0.00%)
         occurrences all number
    1
    0
    Eye disorders
    Anterior chamber cell
         subjects affected / exposed
    0 / 19 (0.00%)
    1 / 21 (4.76%)
         occurrences all number
    0
    2
    Blepharitis
         subjects affected / exposed
    1 / 19 (5.26%)
    0 / 21 (0.00%)
         occurrences all number
    1
    0
    Choroidal neovascularisation
         subjects affected / exposed
    0 / 19 (0.00%)
    2 / 21 (9.52%)
         occurrences all number
    0
    3
    Conjunctival erosion
         subjects affected / exposed
    1 / 19 (5.26%)
    0 / 21 (0.00%)
         occurrences all number
    1
    0
    Conjunctival haemorrhage
         subjects affected / exposed
    4 / 19 (21.05%)
    6 / 21 (28.57%)
         occurrences all number
    4
    9
    Conjunctival hyperaemia
         subjects affected / exposed
    1 / 19 (5.26%)
    0 / 21 (0.00%)
         occurrences all number
    1
    0
    Corneal erosion
         subjects affected / exposed
    0 / 19 (0.00%)
    1 / 21 (4.76%)
         occurrences all number
    0
    1
    Dry eye
         subjects affected / exposed
    1 / 19 (5.26%)
    1 / 21 (4.76%)
         occurrences all number
    2
    2
    Eye discharge
         subjects affected / exposed
    0 / 19 (0.00%)
    1 / 21 (4.76%)
         occurrences all number
    0
    1
    Eye pain
         subjects affected / exposed
    1 / 19 (5.26%)
    0 / 21 (0.00%)
         occurrences all number
    1
    0
    Eyelid oedema
         subjects affected / exposed
    0 / 19 (0.00%)
    1 / 21 (4.76%)
         occurrences all number
    0
    1
    Foreign body sensation in eyes
         subjects affected / exposed
    0 / 19 (0.00%)
    2 / 21 (9.52%)
         occurrences all number
    0
    3
    Lacrimation increased
         subjects affected / exposed
    1 / 19 (5.26%)
    1 / 21 (4.76%)
         occurrences all number
    1
    1
    Macular fibrosis
         subjects affected / exposed
    1 / 19 (5.26%)
    0 / 21 (0.00%)
         occurrences all number
    1
    0
    Metamorphopsia
         subjects affected / exposed
    1 / 19 (5.26%)
    1 / 21 (4.76%)
         occurrences all number
    1
    2
    Ocular discomfort
         subjects affected / exposed
    1 / 19 (5.26%)
    1 / 21 (4.76%)
         occurrences all number
    1
    1
    Pinguecula
         subjects affected / exposed
    1 / 19 (5.26%)
    0 / 21 (0.00%)
         occurrences all number
    2
    0
    Retinal fibrosis
         subjects affected / exposed
    0 / 19 (0.00%)
    2 / 21 (9.52%)
         occurrences all number
    0
    2
    Retinal scar
         subjects affected / exposed
    1 / 19 (5.26%)
    0 / 21 (0.00%)
         occurrences all number
    1
    0
    Subretinal fluid
         subjects affected / exposed
    1 / 19 (5.26%)
    0 / 21 (0.00%)
         occurrences all number
    2
    0
    Vision blurred
         subjects affected / exposed
    0 / 19 (0.00%)
    1 / 21 (4.76%)
         occurrences all number
    0
    1
    Visual acuity reduced
         subjects affected / exposed
    1 / 19 (5.26%)
    1 / 21 (4.76%)
         occurrences all number
    1
    2
    Visual impairment
         subjects affected / exposed
    1 / 19 (5.26%)
    1 / 21 (4.76%)
         occurrences all number
    1
    2
    Vitreous detachment
         subjects affected / exposed
    0 / 19 (0.00%)
    2 / 21 (9.52%)
         occurrences all number
    0
    2
    Vitreous floaters
         subjects affected / exposed
    1 / 19 (5.26%)
    2 / 21 (9.52%)
         occurrences all number
    2
    2
    Gastrointestinal disorders
    Abdominal pain upper
         subjects affected / exposed
    0 / 19 (0.00%)
    1 / 21 (4.76%)
         occurrences all number
    0
    1
    Diarrhoea
         subjects affected / exposed
    1 / 19 (5.26%)
    0 / 21 (0.00%)
         occurrences all number
    1
    0
    Gastrooesophageal reflux disease
         subjects affected / exposed
    1 / 19 (5.26%)
    0 / 21 (0.00%)
         occurrences all number
    1
    0
    Nausea
         subjects affected / exposed
    0 / 19 (0.00%)
    1 / 21 (4.76%)
         occurrences all number
    0
    1
    Skin and subcutaneous tissue disorders
    Actinic keratosis
         subjects affected / exposed
    0 / 19 (0.00%)
    1 / 21 (4.76%)
         occurrences all number
    0
    1
    Hyperhidrosis
         subjects affected / exposed
    0 / 19 (0.00%)
    1 / 21 (4.76%)
         occurrences all number
    0
    1
    Melanosis
         subjects affected / exposed
    1 / 19 (5.26%)
    0 / 21 (0.00%)
         occurrences all number
    1
    0
    Photosensitivity reaction
         subjects affected / exposed
    0 / 19 (0.00%)
    2 / 21 (9.52%)
         occurrences all number
    0
    2
    Sebaceous gland disorder
         subjects affected / exposed
    0 / 19 (0.00%)
    1 / 21 (4.76%)
         occurrences all number
    0
    1
    Renal and urinary disorders
    Chronic kidney disease
         subjects affected / exposed
    1 / 19 (5.26%)
    0 / 21 (0.00%)
         occurrences all number
    1
    0
    Endocrine disorders
    Thyroid mass
         subjects affected / exposed
    1 / 19 (5.26%)
    0 / 21 (0.00%)
         occurrences all number
    1
    0
    Musculoskeletal and connective tissue disorders
    Arthralgia
         subjects affected / exposed
    1 / 19 (5.26%)
    1 / 21 (4.76%)
         occurrences all number
    1
    1
    Back pain
         subjects affected / exposed
    2 / 19 (10.53%)
    0 / 21 (0.00%)
         occurrences all number
    2
    0
    Fibromyalgia
         subjects affected / exposed
    1 / 19 (5.26%)
    0 / 21 (0.00%)
         occurrences all number
    1
    0
    Intervertebral disc protrusion
         subjects affected / exposed
    1 / 19 (5.26%)
    0 / 21 (0.00%)
         occurrences all number
    1
    0
    Muscular weakness
         subjects affected / exposed
    1 / 19 (5.26%)
    0 / 21 (0.00%)
         occurrences all number
    1
    0
    Neck pain
         subjects affected / exposed
    0 / 19 (0.00%)
    1 / 21 (4.76%)
         occurrences all number
    0
    1
    Spinal column stenosis
         subjects affected / exposed
    1 / 19 (5.26%)
    0 / 21 (0.00%)
         occurrences all number
    1
    0
    Spinal osteoarthritis
         subjects affected / exposed
    1 / 19 (5.26%)
    0 / 21 (0.00%)
         occurrences all number
    2
    0
    Infections and infestations
    Bronchitis
         subjects affected / exposed
    1 / 19 (5.26%)
    1 / 21 (4.76%)
         occurrences all number
    1
    1
    Conjunctivitis
         subjects affected / exposed
    1 / 19 (5.26%)
    2 / 21 (9.52%)
         occurrences all number
    1
    2
    Gastroenteritis
         subjects affected / exposed
    0 / 19 (0.00%)
    1 / 21 (4.76%)
         occurrences all number
    0
    1
    Herpes simplex
         subjects affected / exposed
    1 / 19 (5.26%)
    0 / 21 (0.00%)
         occurrences all number
    1
    0
    Hordeolum
         subjects affected / exposed
    0 / 19 (0.00%)
    1 / 21 (4.76%)
         occurrences all number
    0
    1
    Influenza
         subjects affected / exposed
    0 / 19 (0.00%)
    1 / 21 (4.76%)
         occurrences all number
    0
    1
    Rhinitis
         subjects affected / exposed
    1 / 19 (5.26%)
    0 / 21 (0.00%)
         occurrences all number
    1
    0
    Viral upper respiratory tract infection
         subjects affected / exposed
    4 / 19 (21.05%)
    4 / 21 (19.05%)
         occurrences all number
    5
    6
    Metabolism and nutrition disorders
    Hypercholesterolaemia
         subjects affected / exposed
    0 / 19 (0.00%)
    1 / 21 (4.76%)
         occurrences all number
    0
    1
    Hyperglycaemia
         subjects affected / exposed
    1 / 19 (5.26%)
    0 / 21 (0.00%)
         occurrences all number
    1
    0
    Iron deficiency
         subjects affected / exposed
    1 / 19 (5.26%)
    0 / 21 (0.00%)
         occurrences all number
    1
    0

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    27 Apr 2015
    Exclusion criterion no. 4 was changed so that only patients with Type 1 or Type 2 diabetes mellitus with HbA1c > 10% (> 86 mmol/mol) at Screening were excluded from the study. Rationale: a large proportion of wAMD patients who suffered from adult-onset diabetes had the possibility to be included in the study.

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 04:03:55 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA